Employees: 196
Size 4D Molecular Therapeutics (FDMT) is a United States Health Care company (Biotechnology) with a market value of $578M, the 2568th largest of 3,085 United States companies the cockpit tracks. Shares closed at $10.46 on 18 Nov 2026.
Performance Over six months the shares gained 23.5%, against -20.4% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 19 in its peer set.
Growth Revenue grew 79,952.5% over the last twelve months (peer median +9.1%); the operating margin is -226.1% (peer median -49.9%).
Valuation It trades at 3.2× enterprise value to sales against a peer median of 3.9× (7th cheapest of 16).
Short interest Short interest is 19.7% of the free float (30 Oct 2026).
Next results Next results expected around 26 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $96.1M | $85.2M | $37,000 | $20.7M | $3.13M |
| Revenue growth | — | +230,195% | -100% | +562% | — |
| Gross profit | $87.9M | $77.6M | -$6.67M | $15.0M | -$751,000 |
| EBITDA | -$209M | -$152M | -$181M | -$107M | -$106M |
| Net income | -$200M | -$140M | -$161M | -$101M | -$107M |
| Free cash flow | -$166M | -$110M | -$138M | -$78.6M | -$98.2M |
| Capital expenditure | $34,000 | $536,000 | $3.79M | $2.77M | $11.5M |
| Total debt | $38.4M | $21.4M | $24.6M | $14.7M | $16.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | FDMT | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -20.1% | -12.2% | 5th lowest of 21 |
| 6-month return | +23.5% | -20.4% | 2nd highest of 19 |
| Distance from 52-week high | -38.2% | -49.8% | 6th highest of 21 |
| Revenue growth (TTM) | +79,952.5% | +9.1% | highest of 17 |
| Operating margin | -226.1% | -49.9% | 6th lowest of 17 |
| EV / Sales | 3.2× | 3.9× | 7th cheapest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| 4D Molecular Therapeutics FDMT | United States | $578M | +23% | +79,952% | -226% | 3.2× | n/a | n/a |
| Ascletis Pharma 1672.HK | Hong Kong | $571M | -72% | -59% | -71,976% | 1,794.8× | n/a | n/a |
| Genfit GNFT.PA | France | $571M | +22% | +28% | -130% | 11.0× | 39.8% | +143.5% |
| Alebund Pharmaceuticals (Jiangsu) 9637.HK | Hong Kong | $595M | n/a | +674% | -495% | 26.8× | n/a | n/a |
| Boji Medical Technology 300404.SZ | China | $561M | -6% | +32% | 4% | 3.4× | 31.9% | +27.2% |
| Sana Biotechnology SANA | United States | $554M | -41% | n/a | n/a | n/a | n/a | n/a |
| Hvsen Biotechnology 300871.SZ | China | $553M | -22% | +2% | 17% | 2.3× | n/a | n/a |
| Anhui Huaheng Biotechnology 688639.SS | China | $605M | -45% | +7% | 3% | 1.9× | n/a | n/a |
| Surrozen SRZN | United States | $605M | +17% | +192% | -485% | 48.5× | n/a | n/a |
| Design Therapeutics DSGN | United States | $606M | -15% | n/a | n/a | n/a | n/a | n/a |
| Wave Life Sciences WVE | United States | $546M | -55% | -35% | -321% | 2.2× | n/a | n/a |
| Climb Bio CLYM | United States | $546M | -12% | n/a | n/a | n/a | n/a | n/a |
| Frontage 1521.HK | Hong Kong | $542M | +113% | +10% | 8% | 2.3× | 14.3% | +15.4% |
| Getein Biotech 603387.SS | China | $625M | -13% | +8% | 21% | 2.6× | -8.9% | -1.3% |
| Janux Therapeutics JANX | United States | $631M | -28% | +133% | -599% | n/a | n/a | n/a |
| Shenzhen Weiguang Biological Products 002880.SZ | China | $633M | -27% | 0% | 18% | 4.4× | n/a | n/a |
| Geron GERN | United States | $638M | -21% | +19% | -8% | 2.8× | n/a | n/a |
| Beijing Bohui Innovation Biotechnology 300318.SZ | China | $518M | -20% | -1% | -13% | 6.2× | n/a | n/a |
| Shouyao Holdings Beijing 688197.SS | China | $653M | -26% | +4,564% | -92% | 38.1× | n/a | n/a |
| LongBio Pharma (Suzhou) 1779.HK | Hong Kong | $510M | n/a | n/a | n/a | n/a | n/a | n/a |
| Valneva VLA.PA | France | $508M | -6% | -27% | -87% | 3.9× | n/a | n/a |